2.Selection criteria and colpotomic approach for safe minimally invasive radical hysterectomy in early-stage cervical cancer
Tae-Wook KONG ; Joo-Hyuk SON ; Jiheum PAEK ; Suk-Joon CHANG ; Hee-Sug RYU
Journal of Gynecologic Oncology 2020;31(1):e7-
Objective:
To evaluate oncologic outcomes of minimally invasive radical hysterectomy (RH) in early cervical cancer before and after the application of parametrial invasion (PMI) criterion on magnetic resonance imaging (MRI) and vaginal colpotomy (VC).
Methods:
A total of 216 International Federation of Gynecology and Obstetrics stage IB–IIA cervical cancer patients who underwent minimally invasive RH was identified between April 2006 and October 2018. Patients were classified into the pre-PMI intracorporeal or VC (IVC) (n=117) and post-PMI VC groups (n=99). In the pre-PMI IVC group, PMI criterion (intact stromal ring) on MRI was not applied and the patients received IVC. In the post-PMI VC group, surgical candidates were selected using the PMI criterion on MRI and all patients received VC only. Oncologic outcomes and prognostic factors associated with disease recurrence were analyzed.
Results:
The rate of positive vaginal cuff margins in the pre-PMI IVC group was higher than that in the post-PMI VC group (11.1% vs. 1.0%, p=0.003). Two-year disease-free survival was different between the 2 groups (84.5% in pre-PMI IVC vs. 98.0% in post-PMI VC groups, p=0.005). Disrupted stromal ring on MRI (hazard ratio [HR]=20.321; 95% confidence interval [CI]=4.903–84.218; p<0.001) and intracorporeal colpotomy (HR=3.059; 95% CI=1.176–7.958; p=0.022) were associated with recurrence.
Conclusion
The intact cervical stromal ring on MRI might identify the low-risk group of patients in terms of PMI and lymphovascular/stromal invasion in early cervical cancer. Minimally invasive RH should be performed in optimal candidates with an intact stromal ring on MRI, using VC.
3.Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma.
Joo Hyuk SON ; Seokyoung YOON ; Seokyung KIM ; Tae Wook KONG ; Jiheum PAEK ; Suk Joon CHANG ; Hee Sug RYU
Obstetrics & Gynecology Science 2019;62(1):27-34
OBJECTIVE: This study aimed to analyze the clinical features of clear cell carcinoma in relation to endometriosis and to determine an appropriate surveillance strategy for the early detection of malignant transformation of endometrioma in asymptomatic patients. METHODS: We retrospectively reviewed the clinicopathologic data of 50 patients with ovarian clear cell carcinoma. Clinicopathologic characteristics, treatment outcomes, and the association between endometriosis and the risk of malignant transformation were analyzed. RESULTS: Ten (20%) patients had been diagnosed with endometrioma before the diagnosis of clear cell carcinoma. The median period from the diagnosis of endometrioma to clear cell carcinoma diagnosis was 50 months (range, 12–213 months). After complete staging surgery, histological confirmation of endometriosis was possible in 35 (70%) patients. Of the 50 patients, 39 (78%) had not undergone any gynecologic surveillance until the onset of symptoms, at which time many of them presented with a rapidly growing pelvic mass (median 10 cm, range 4.6–25 cm). With the exception of 2 patients, all cancer diagnoses were made when the patients were in their late thirties, and median tumor size was found to increase along with age. Asymptomatic patients (n=11) who had regular gynecologic examinations were found to have a relatively smaller tumor size, lesser extent of tumor spread, and lower recurrence rate (P=0.011, 0.283, and 0.064, respectively). The presence of endometriosis was not related to the prognosis. CONCLUSION: Considering the duration of malignant transformation and the timing of cancer diagnosis, active surveillance might be considered from the age of the mid-thirties, with at least a 1-year interval, in patients with asymptomatic endometrioma.
Cell Transformation, Neoplastic
;
Diagnosis
;
Endometriosis*
;
Female
;
Humans
;
Prognosis
;
Recurrence
;
Retrospective Studies
4.Asian Society of Gynecologic Oncology International Workshop 2018
Tae Wook KONG ; Hee Sug RYU ; Seung Cheol KIM ; Takayuki ENOMOTO ; Jin LI ; Kenneth H KIM ; Seung Hyuk SHIM ; Peng Hui WANG ; Suwanit THERASAKVICHYA ; Yusuke KOBAYASHI ; Maria LEE ; Tingyan SHI ; Shin Wha LEE ; Mikio MIKAMI ; Satoru NAGASE ; Myong Cheol LIM ; Jianliu WANG ; Sarikapan WILAILAK ; Sang Wun KIM ; Sook Hee HONG ; David SP TAN ; Masaki MANDAI ; Suk Joon CHANG ; Ruby Yun Ju HUANG ; Kimio USHIJIMA ; Jung Yun LEE ; Xiaojun CHEN ; Kazunori OCHIAI ; Taek Sang LEE ; Bingyi YANG ; Farhana KALAM ; Qiaoying LV ; Mohd Faizal AHMAD ; Muhammad Rizki YAZNIL ; Kanika Batra MODI ; Manatsawee MANOPUNYA ; Dae Hoon JEONG ; Arb aroon LERTKHACHONSUK ; Hyun Hoon CHUNG ; Hidemichi WATARI ; Seob JEON
Journal of Gynecologic Oncology 2019;30(2):e39-
The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.
Antineoplastic Agents
;
Asian Continental Ancestry Group
;
Drug Therapy
;
Education
;
Endometrial Neoplasms
;
Female
;
Gyeonggi-do
;
Humans
;
Immunotherapy
;
Korea
;
Ovarian Neoplasms
;
Radiotherapy
;
Uterine Cervical Neoplasms
5.Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study
Miseon KIM ; Byung Su KWON ; Ha Kyun CHANG ; Seungmee LEE ; Suk Joon CHANG ; Jin Young CHOI ; Sang Yoon PARK ; Maria LEE ; Hee Sug RYU ; Yong Beom KIM
Journal of Gynecologic Oncology 2019;30(3):e44-
OBJECTIVE: To compare the survival outcomes of adjuvant radiotherapy and chemotherapy in women with uterine-confined endometrial cancer with uterine papillary serous carcinoma (UPSC) or clear cell carcinoma (CCC). METHODS: Medical records of 80 women who underwent surgical staging for endometrial cancer were retrospectively reviewed. Stage I UPSC and CCC were pathologically confirmed after surgery. Survival outcomes were compared between the adjuvant radiotherapy and chemotherapy groups. RESULTS: Fifty-four (67.5%) and 26 (32.5%) women had UPSC and CCC, respectively. Adjuvant therapy was administered to 59/80 (73.8%) women (25 radiotherapy and 34 chemotherapy). High preoperative serum cancer antigen-125 level (25.1±20.2 vs. 11.5±6.5 IU/mL, p < 0.001), open surgery (71.2% vs. 28.6%, p=0.001), myometrial invasion (MI) ≥1/2 (33.9% vs. 0, p=0.002), and lymphovascular space invasion (LVSI; 28.8% vs. 4.8%, p=0.023) were frequent in women who received adjuvant therapy compared to those who did not. However, the histologic type, MI ≥1/2, and LVSI did not differ between women who received adjuvant radiotherapy and those who received chemotherapy. The 5-year progression-free survival (78.9% vs. 80.1%, p>0.999) and overall survival (77.5% vs. 87.8%, p=0.373) rates were similar between the groups. Neither radiotherapy (hazard ratio [HR]=1.810; 95% confidence interval [CI]=0.297–11.027; p=0.520) nor chemotherapy (HR=1.638; 95% CI=0.288–9.321; p=0.578) after surgery was independently associated with disease recurrence. CONCLUSION: Our findings showed similar survival outcomes for adjuvant radiotherapy and chemotherapy in stage I UPSC and CCC of the endometrium. Further large study with analysis stratified by MI or LVSI is required.
Adenocarcinoma, Clear Cell
;
Adenocarcinoma, Papillary
;
Chemotherapy, Adjuvant
;
Disease-Free Survival
;
Drug Therapy
;
Endometrial Neoplasms
;
Endometrium
;
Female
;
Humans
;
Medical Records
;
Radiotherapy
;
Radiotherapy, Adjuvant
;
Recurrence
;
Retrospective Studies
6.ASGO 5th International Workshop on Gynecologic Oncology.
Joo Hyuk SON ; Suk Joon CHANG ; Hee Sug RYU
Journal of Gynecologic Oncology 2018;29(6):e101-
No abstract available.
Education*
7.Adaptation of Isolation Guidelines for Health Care Settings
Jae Geum RYU ; Jae Sim JEONG ; Ihn Sook JEONG ; Jeong Hye KIM ; Eun Young HONG ; Hyang Sook KIM ; Young Sun JUNG ; Jeong Soon KWON ; Ji Young LEE ; Ji Youn CHOI ; Kyung Sug KIM ; Eun Hyun KIM ; Gyeong Suk CHA ; Eun Jin KIM ; Kyung Hee PARK ; Hyun Ju SEO
Journal of Korean Clinical Nursing Research 2018;24(2):209-226
PURPOSE: This purpose of this study was to develop evidence-based practice guideline for isolation in health care settings to prevent transmission of infectious diseases utilizing guideline adaption process. METHODS: The process of guideline adaptation was performed according to the Korean hospital nurses association's guideline adaptation manual which consisted of three main phases, 9 modules, and 24 steps. RESULTS: The adapted isolation guideline consisted of introduction, overview of isolation guideline, summary of recommendations, recommendations, references, and appendices. The guideline includes 224 recommendations in 4 sections which are organizational administration, standard precautions, transmission-based precautions, and education/counselling. CONCLUSION: The adapted isolation guideline is recommended to be disseminated and utilized by nurses and clinicians nationwide to improve the isolation practices for infected or colonized patients with communicable diseases and to decrease the transmission of infections in the healthcare settings.
Colon
;
Communicable Diseases
;
Delivery of Health Care
;
Disease Transmission, Infectious
;
Evidence-Based Nursing
;
Evidence-Based Practice
;
Humans
;
Infection Control
;
Patient Isolation
8.Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization.
Tae Wook KONG ; Suk Joon CHANG ; Jinoo KIM ; Jiheum PAEK ; Su Hyun KIM ; Je Hwan WON ; Hee Sug RYU
Journal of Gynecologic Oncology 2016;27(4):e44-
OBJECTIVE: To evaluate risk factors for massive lymphatic ascites after laparoscopic retroperitoneal lymphadenectomy in gynecologic cancer and the feasibility of treatments using intranodal lymphangiography (INLAG) with glue embolization. METHODS: A retrospective analysis of 234 patients with gynecologic cancer who received laparoscopic retroperitonal lymphadenectomy between April 2006 and November 2015 was done. In June 2014, INLAG with glue embolization was initiated to manage massive lymphatic ascites. All possible clinicopathologic factors related to massive lymphatic ascites were determined in the pre-INLAG group (n=163). Clinical courses between pre-INLAG group and post-INLAG group (n=71) were compared. RESULTS: In the pre-INLAG group (n=163), four patients (2.5%) developed massive lymphatic ascites postoperatively. Postoperative lymphatic ascites was associated with liver cirrhosis (three cirrhotic patients, p<0.001). In the post-INLAG group, one patient with massive lymphatic ascites had a congestive heart failure and first received INLAG with glue embolization. She had pelvic drain removed within 7 days after INLAG. The mean duration of pelvic drain and hospital stay decreased after the introduction of INLAG (13.2 days vs. 10.9 days, p=0.001; 15.2 days vs. 12.6 days, p=0.001). There was no evidence of recurrence after this procedure. CONCLUSION: Underlying medical conditions related to the reduced effective circulating volume, such as liver cirrhosis and heart failure, may be associated with massive lymphatic ascites after retroperitoneal lymphadenectomy. INLAG with glue embolization can be an alternative treatment options to treat leaking lymphatic channels in patients with massive lymphatic leakage.
Adult
;
Aged
;
Ascites/*etiology/therapy
;
Embolization, Therapeutic/*methods
;
Female
;
Genital Neoplasms, Female/*surgery
;
Humans
;
Lymph Node Excision/*adverse effects
;
*Lymphography
;
Middle Aged
;
Postoperative Complications/*etiology
;
Retrospective Studies
9.Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization.
Tae Wook KONG ; Suk Joon CHANG ; Jinoo KIM ; Jiheum PAEK ; Su Hyun KIM ; Je Hwan WON ; Hee Sug RYU
Journal of Gynecologic Oncology 2016;27(4):e44-
OBJECTIVE: To evaluate risk factors for massive lymphatic ascites after laparoscopic retroperitoneal lymphadenectomy in gynecologic cancer and the feasibility of treatments using intranodal lymphangiography (INLAG) with glue embolization. METHODS: A retrospective analysis of 234 patients with gynecologic cancer who received laparoscopic retroperitonal lymphadenectomy between April 2006 and November 2015 was done. In June 2014, INLAG with glue embolization was initiated to manage massive lymphatic ascites. All possible clinicopathologic factors related to massive lymphatic ascites were determined in the pre-INLAG group (n=163). Clinical courses between pre-INLAG group and post-INLAG group (n=71) were compared. RESULTS: In the pre-INLAG group (n=163), four patients (2.5%) developed massive lymphatic ascites postoperatively. Postoperative lymphatic ascites was associated with liver cirrhosis (three cirrhotic patients, p<0.001). In the post-INLAG group, one patient with massive lymphatic ascites had a congestive heart failure and first received INLAG with glue embolization. She had pelvic drain removed within 7 days after INLAG. The mean duration of pelvic drain and hospital stay decreased after the introduction of INLAG (13.2 days vs. 10.9 days, p=0.001; 15.2 days vs. 12.6 days, p=0.001). There was no evidence of recurrence after this procedure. CONCLUSION: Underlying medical conditions related to the reduced effective circulating volume, such as liver cirrhosis and heart failure, may be associated with massive lymphatic ascites after retroperitoneal lymphadenectomy. INLAG with glue embolization can be an alternative treatment options to treat leaking lymphatic channels in patients with massive lymphatic leakage.
Adult
;
Aged
;
Ascites/*etiology/therapy
;
Embolization, Therapeutic/*methods
;
Female
;
Genital Neoplasms, Female/*surgery
;
Humans
;
Lymph Node Excision/*adverse effects
;
*Lymphography
;
Middle Aged
;
Postoperative Complications/*etiology
;
Retrospective Studies
10.Pelvic Castleman's disease presenting as an adnexal tumor in a young woman.
Jisun LEE ; Jiheum PAEK ; Yong Hee LEE ; Tae Wook KONG ; Suk Joon CHANG ; Hee Sug RYU
Obstetrics & Gynecology Science 2015;58(4):323-326
Castleman's disease (CD) is a rare benign disorder of unknown etiology characterized by proliferation of lymphoid tissues. Seventy percent of this tumor occurs in the mediastinum and it is seldom found in neck, pancreas or pelvis. We report a case of asymptomatic pelvic CD initially presenting as an adnexal tumor in a 27-year-old woman. Initial transvaginal sonography revealed 7-cm-sized hyperechoic mass adjacent to the right ovary and the following abdominal computed tomography scanning showed the same sized mass located on the right extraperitoneal pelvic cavity. Laparoscopic mass excision was performed without any complication and pathological diagnosis was made as CD. CD should be included in the differential diagnosis of female pelvic masses which are noted in the pelvic cavity. In this report, we review the clinicopathological findings in a presentation of CD.
Adult
;
Diagnosis
;
Diagnosis, Differential
;
Female
;
Giant Lymph Node Hyperplasia*
;
Humans
;
Lymphoid Tissue
;
Mediastinum
;
Neck
;
Ovary
;
Pancreas
;
Pelvis

Result Analysis
Print
Save
E-mail